Literature DB >> 24794862

Prognostic significance of novel ¹⁸F-FDG PET/CT defined tumour variables in patients with oesophageal cancer.

Kieran G Foley1, Patrick Fielding2, Wyn G Lewis3, Alex Karran4, David Chan5, Paul Blake6, S Ashley Roberts7.   

Abstract

PURPOSE: (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) combined with computed tomography (PET/CT) is now established as a routine staging investigation of oesophageal cancer (OC). The aim of the study was to determine the prognostic significance of PET/CT defined tumour variables including maximum standardised uptake value (SUVmax), tumour length (TL), metastatic length of disease (MLoD), metabolic tumour volume (MTV), total lesion glycolysis (TLG) and total local nodal metastasis count (PET/CT LNMC).
MATERIALS AND METHODS: 103 pre-treatment OC patients (76 adenocarcinoma, 25 squamous cell carcinoma, 1 poorly differentiated and 1 neuroendocrine tumour) were staged using PET/CT. The prognostic value of the measured tumour variables were tested using log-rank analysis of the Kaplan-Meier method and Cox's proportional hazards method. Primary outcome measure was survival from diagnosis.
RESULTS: Univariate analysis showed all variables to have strong statistical significance in relation to survival. Multivariate analysis demonstrated three variables that were significantly and independently associated with survival; MLoD (HR 1.035, 95% CI 1.008-1.064, p=0.011), TLG (HR 1.002, 95% CI 1.000-1.003, p=0.018) and PET/CT LNMC (HR 0.048-0.633, 95% CI 0.005-2.725, p=0.015).
CONCLUSION: MLoD, TLG, and PET/CT LNMC are important prognostic indicators in OC. This is the first study to demonstrate an independent statistical association between TLG, MLoD and survival by multivariable analysis, and highlights the value of staging OC patients with PET/CT using functional tumour variables. Crown
Copyright © 2014. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Oesophageal cancer; PET/CT; Prognosis; Staging

Mesh:

Substances:

Year:  2014        PMID: 24794862     DOI: 10.1016/j.ejrad.2014.03.031

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  10 in total

1.  Change in volume parameters induced by neoadjuvant chemotherapy provide accurate prediction of overall survival after resection in patients with oesophageal cancer.

Authors:  Dietmar Tamandl; Richard M Gore; Barbara Fueger; Patrick Kinsperger; Michael Hejna; Matthias Paireder; Alexander Haug; Sebastian F Schoppmann; Ahmed Ba-Ssalamah
Journal:  Eur Radiol       Date:  2015-06-05       Impact factor: 5.315

2.  Prognostic utility of diffusion-weighted MRI in oesophageal cancer: is apparent diffusion coefficient a potential marker of tumour aggressiveness?

Authors:  Francesco Giganti; Annalaura Salerno; Alessandro Ambrosi; Damiano Chiari; Elena Orsenigo; Antonio Esposito; Luca Albarello; Elena Mazza; Carlo Staudacher; Alessandro Del Maschio; Francesco De Cobelli
Journal:  Radiol Med       Date:  2015-09-21       Impact factor: 3.469

3.  18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients.

Authors:  Elena Elimova; Xuemei Wang; Elba Etchebehere; Hironori Shiozaki; Yusuke Shimodaira; Roopma Wadhwa; Venkatram Planjery; Nikolaos Charalampakis; Mariela A Blum; Wayne Hofstetter; Jeff H Lee; Brian R Weston; Manoop S Bhutani; Jane E Rogers; Dipen Maru; Heath D Skinner; Homer A Macapinlac; Jaffer A Ajani
Journal:  Eur J Cancer       Date:  2015-08-28       Impact factor: 9.162

4.  Cyclo-oxygenase-2 expression is associated with mean standardised uptake value on 18F-Fluorodeoxyglucose positron emission tomography in oesophageal adenocarcinoma.

Authors:  Kieran G Foley; Adam Christian; James Peaker; Christopher Marshall; Emiliano Spezi; Howard Kynaston; Ashley Roberts
Journal:  Br J Radiol       Date:  2019-05-08       Impact factor: 3.039

5.  Prediction of lymph node metastases using pre-treatment PET radiomics of the primary tumour in esophageal adenocarcinoma: an external validation study.

Authors:  Chong Zhang; Zhenwei Shi; Petros Kalendralis; Phil Whybra; Craig Parkinson; Maaike Berbee; Emiliano Spezi; Ashley Roberts; Adam Christian; Wyn Lewis; Tom Crosby; Andre Dekker; Leonard Wee; Kieran G Foley
Journal:  Br J Radiol       Date:  2020-12-11       Impact factor: 3.039

Review 6.  Present and future roles of FDG-PET/CT imaging in the management of gastrointestinal cancer: an update.

Authors:  Kazuhiro Kitajima; Masatoyo Nakajo; Hayato Kaida; Ryogo Minamimoto; Kenji Hirata; Masakatsu Tsurusaki; Hiroshi Doi; Yoshiko Ueno; Keitaro Sofue; Yukihisa Tamaki; Koichiro Yamakado
Journal:  Nagoya J Med Sci       Date:  2017-11       Impact factor: 1.131

7.  Diagnostic value of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for preoperative lymph node metastasis of esophageal cancer: A meta-analysis.

Authors:  Jingfeng Hu; Dengyan Zhu; Yang Yang
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

8.  Prognostic Significance of 2-Deoxy-2-[18F]-Fluoro-D-Glucose PET/CT in Patients With Locally Advanced Esophageal Cancer Undergoing Neoadjuvant Chemoradiotherapy Before Surgery: A Nonparametric Approach.

Authors:  Assuero Giorgetti; Giovanni Pallabazzer; Andrea Ripoli; Biagio Solito; Dario Genovesi; Monica Lencioni; Maria Grazia Fabrini; Simone D'Imporzano; Laura Pieraccini; Paolo Marzullo; Stefano Santi
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

9.  Glucose Drives Growth Factor-Independent Esophageal Cancer Proliferation via Phosphohistidine-Focal Adhesion Kinase Signaling.

Authors:  Jianliang Zhang; Irwin H Gelman; Eriko Katsuta; Yuanzi Liang; Xue Wang; Jun Li; Jun Qu; Li Yan; Kazuaki Takabe; Steven N Hochwald
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2019-03-02

10.  Prognostic value of 18F-FDG PET /CT metabolic parameters in patients with locally advanced pancreatic Cancer treated with stereotactic body radiation therapy.

Authors:  Shengnan Ren; Xiaofei Zhu; Anyu Zhang; Danni Li; Changjing Zuo; Huojun Zhang
Journal:  Cancer Imaging       Date:  2020-03-10       Impact factor: 3.909

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.